Table of Contents 2
List of Tables 5
List of Figures 5
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 27
In Progress Trials by Phase 28
Clinical Trials by Trial Status 29
Clinical Trials by End Point Status 31
Subjects Recruited Over a Period of Time 32
Clinical Trials by Sponsor Type 33
Prominent Sponsors 34
Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 36
Prominent Drugs 38
Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 39
Jun 14, 2016: Celator Pharmaceuticals Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia 39
Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association 40
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1425 at 21st Congress of the European Hematology Association 41
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association 41
Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 42
Jun 08, 2016: Actinium to Present at BIO International Convention to Provide Update on Actimab-A Program 43
Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 43
Jun 06, 2016: Celator Pharmaceuticals Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival 44
Jun 06, 2016: Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting 45
Jun 06, 2016: Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 46
Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting 46
Jun 06, 2016: Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting 48
Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers 48
Jun 01, 2016: Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial 49
May 31, 2016: Mundipharma EDO Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101 50
May 25, 2016: Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 51
May 25, 2016: GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine 52
May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting 52
May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting 53
May 19, 2016: Celator Pharmaceuticals Announces Upcoming Phase 3 Data Presentations at American Society of Clinical Oncology and European Hematology Association 54
May 19, 2016: Syros Pharmaceuticals to Present on SY-1425 at 21st Congress of the European Hematology Association 54
May 18, 2016: AbbVie To Present Data on Venclexta (venetoclax) at ASCO 2016 55
May 18, 2016: Actinium Announces Webinar to Discuss Results of the Actimab-A Phase 1 Trial and Key Findings From the HuM195-Alpha Program 55
May 16, 2016: Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 56
May 11, 2016: Clinical data of Medigene dendritic cell vaccines in AML presented at CIMT conference 57
May 11, 2016: Clinical data of Medigene's dendritic cell vaccines in AML presented at CIMT conference 57
May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 58
Apr 25, 2016: Celator Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS Compared to Standard Treatment for Acute Myeloid Leukemia (AML) 58
Apr 25, 2016: GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference 59
Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial — Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 59
Apr 21, 2016: Celator Pharmaceuticals to Present Phase 3 Data at 2016 American Society of Clinical Oncology Annual Meeting 60
Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia 60
Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 61
Apr 18, 2016: Calithera Biosciences Announces Preclinical Presentation of CB-839 at the American Association for Cancer Research Annual Meeting 2016 61
Apr 18, 2016: Celator Pharmaceuticals Announces Data for VYXEOS in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting 62
Apr 18, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia 62
Apr 18, 2016: Celator Pharmaceuticals Announces Positive Data for VYXEOS in FLT3-ITD Mutated Acute Myeloid Leukemia Cells Derived from Patients with Newly Diagnosed AML 63
Apr 18, 2016: ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia 63
Apr 12, 2016: UPDATE – Actinium Announces Selection of Zevacor Pharma for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial 64
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 64
Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) 65
Clinical Trial Profile Snapshots 68
Appendix 2057
Abbreviations 2057
Definitions 2057
Research Methodology 2058
Secondary Research 2058
About GlobalData 2059
Contact Us 2059
Disclaimer 2059
Source 2060
